Replimune: 3 Key Takeaways for Long-Term Investors

Replimune ended the second quarter with $307.8 million in cash. Over 15 institutions wrote prescriptions within 20 business days.

The Motley Fool • a day ago

Replimune Group, Inc. (REPL) Q2 2027 Earnings Call Transcript

Replimune Group, Inc. ( REPL ) Q2 2027 Earnings Call October 28, 2026 8:00 AM EDT Company Participants Arleen Goldenberg Sushil Patel - CEO & Director Michelle DiNapoli - Chief Commercial Officer Emily Hill - Chief Financial Officer Conference Call Participants Evan Seigerman - BMO Capital Markets Equity Research Allison Bratzel - Piper Sandler & Co., Research Division Anupam Rama - JPMorgan Chase & Co, Research Division Jiale Song - Jefferies LLC, Research Division Mubeen Mosaheb Romy O'Connor - Van Lanschot Kempen NV Presentation Operator Good day, and thank you for standing by. Welcome to the Replimune's Second Quarter Fiscal 2027 Earnings Conference Call.

Seeking Alpha • Oct 28, 2026

Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update

TUDRIQEV first delivered to patients for advanced melanoma on October 6th More than 15 institutions have prescribed TUDRIQEV Management will host a webcast today at 8:00 a.m. ET WOBURN, Mass.

GlobeNewsWire • Oct 28, 2026

Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026

WOBURN, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it will host a conference call on Wednesday, October 28, 2026, at 8:00 a.m. ET to discuss its financial results and provide corporate update for the fiscal second quarter ended September 30, 2026.

GlobeNewsWire • Oct 22, 2026

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for Replimune (REPL) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 10/5/2026

GlobeNewsWire • Oct 5, 2026

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPL

Replimune told investors its RP1 resubmission was a complete response to the FDA's prior deficiency letter and that commercial launch teams stood ready; the agency's April 2026 rejection letter stated the study design concerns it had previously communicated were never addressed, and REPL shares fell to $1.70. Replimune told investors its RP1 resubmission was a complete response to the FDA's prior deficiency letter and that commercial launch teams stood ready; the agency's April 2026 rejection letter stated the study design concerns it had previously communicated were never addressed, and REPL shares fell to $1.70.

GlobeNewsWire • Oct 5, 2026

REPLIMUNE CLASS ACTION DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Urgently Reminds Replimune Group Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 5th

If you purchased or acquired Replimune securities between October 20, 2025 and April 10, 2026 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at  investigations@bespc.com or by telephone at (212) 355-4648.

GlobeNewsWire • Oct 2, 2026

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL

NEW YORK, Oct. 1, 2026 /PRNewswire/ --  Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

PRNewsWire • Oct 1, 2026

SueWallSt Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - REPL

Important Information Regarding Section 20(a) Individual Liability Claims: CEO Sushil Patel and CFO Emily Hill are named as individual defendants in a securities class action alleging Replimune's RP1 disclosures omitted unresolved FDA study-design concerns. NEW YORK, Oct. 1, 2026 /PRNewswire/ -- SueWallSt alerts investors in Replimune Group, Inc. (NASDAQ: REPL) of a pending securities class action brought on behalf of shareholders who purchased securities between October 20, 2025 and April 10, 2026.

PRNewsWire • Oct 1, 2026

Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma

ReplimuneConnect Plus a comprehensive program that provides dedicated support and resources to help eligible patients access TUDRIQEV in the U.S. now live ReplimuneConnect Plus a comprehensive program that provides dedicated support and resources to help eligible patients access TUDRIQEV in the U.S. now live

GlobeNewsWire • Oct 1, 2026